CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Gross Profit
-€62.5m
CAGR 3-Years
N/A
CAGR 5-Years
-66%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Gross Profit
€3.2B
CAGR 3-Years
97%
CAGR 5-Years
95%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Gross Profit
€170.7m
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Gross Profit
€240m
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Gross Profit
€22.9m
CAGR 3-Years
44%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Gross Profit?
Gross Profit
-62.5m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Gross Profit amounts to -62.5m EUR.

What is CureVac NV's Gross Profit growth rate?
Gross Profit CAGR 5Y
-66%

Over the last year, the Gross Profit growth was 32%.

Back to Top